Page 583 - Read Online

Cordover et al. J Cancer Metastasis Treat 2020;6:45 I http://dx.doi.org/10.20517/2394-4722.2020.101 Page 19 of 19

myeloma. Blood 2017;129:2233-45.
118. Mohammad RM, Li Y, Muqbil I, et al. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug
resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases 2019;10:367-77.
119. Takao S, Chien W, Madan V, et al. Targeting the vulnerability to NAD depletion in B-cell acute lymphoblastic leukemia. Leukemia
+
2018;32:616-25.
120. Yoshino J, Baur JA, Imai SI. NAD intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27:513-28.
+
121. Cordover E, Wei J, Patel C, et al. KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative
breast cancer cells. Chem Res Toxicol 2020;33:482-91.
122. Rane CK, Patel M, Cai L, Senapedis W, Baloglu E, Minden A. Decrypting the PAK4 transcriptome profile in mammary tumor forming
cells using next generation sequencing. Genomics 2017:248-56.
123. Wintheiser GA, Silberstein P. Physiology, tyrosine kinase receptors. In StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
124. Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci 2018;19:3491.